We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Gentronix Agrees Genotoxicity Safety Screening Agreement with GSK for Greenscreen HC
News

Gentronix Agrees Genotoxicity Safety Screening Agreement with GSK for Greenscreen HC

Gentronix Agrees Genotoxicity Safety Screening Agreement with GSK for Greenscreen HC
News

Gentronix Agrees Genotoxicity Safety Screening Agreement with GSK for Greenscreen HC

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Gentronix Agrees Genotoxicity Safety Screening Agreement with GSK for Greenscreen HC"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Gentronix Limited [Manchester, UK] has announced that it has entered into an agreement to provide GlaxoSmithKline (GSK) with its novel genotoxicity detection assay GreenScreen HC.

GreenScreen HC is said to be the first human cell based assay technology that combines high sensitivity for detecting genotoxic chemicals with high specificity for reducing false positive results. The assay is amenable to high throughput screening, provides additional data for safety profiling, consumes very low quantities of compound and gives rapid results.

The proprietary reporter based assay detects all known classes of genotoxic agent and utilizes Green Fluorescent Protein in order to detect GADD-45a up-regulation which is a key indicator of DNA damage.

John Nicholson, CEO and Chairman of Gentronix said ‘we have worked with GSK previously on the early validation of our technology and are delighted that they will be incorporating GreenScreen HC into their safety evaluation activities. This agreement provides important validation of our technology and demonstrates the value we bring to our customers’

Financial terms of the agreement were not released.
Advertisement